^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
KANJINTI is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer.
Secondary therapy:
paclitaxel; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; carboplatin + docetaxel; docetaxel + doxorubicin hydrochloride + cyclophosphamide